We treated 17 patients who had Philadelphia-chromosome-positive chronic myelogenous leukemia (4 of whom had not received therapy and 13 of whom had been treated with hydroxyurea or busulfan for less than six months) with recombinant human interferon alpha A (Roferon-A). The interferon was given as 5 X 10(6) units per square meter of body-surface area per day intramuscularly during induction therapy. Fourteen patients responded to the treatment, of whom 13 had a hematologic remission and 1 had a partial hematologic remission. The median number of white cells in those patients declined from 60.9 X 10(3) to 3.4 X 10(3) per microliter, and the median number of platelets decreased from 476 X 10(3) to 231 X 10(3) per microliter. Among the five responding patients who had splenomegaly before treatment, the spleen size returned to normal in four and decreased by 75 percent in one, although it remained enlarged. Bone marrow cellularity declined from a median of 92.5 percent to a median of 57.5 percent. In six of the patients with hematologic remission, complete suppression of Philadelphia cells was observed on at least one examination. Of the 14 patients who responded, 11 have received the interferon therapy for 9 to 15 months. One patient relapsed during the treatment, and the treatment has been temporarily interrupted in two patients because of toxicity. These data are preliminary and will need further confirmation, but they suggest that recombinant human interferon alpha A is effective in inducing hematologic remission in most patients with benign-phase chronic myelogenous leukemia and in suppressing the Philadelphia chromosome in some of these patients.
This article has been cited by other articles:
Schiffer, C. A.
(2007). BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. NEJM
357: 258-265
[Full Text]
Stone, R. M.
(2004). Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach. The Oncologist
9: 259-270
[Abstract][Full Text]
Radich, J. P., Gooley, T., Bensinger, W., Chauncey, T., Clift, R., Flowers, M., Martin, P., Slattery, J., Sultan, D., Appelbaum, F. R.
(2003). HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood
102: 31-35
[Abstract][Full Text]
Sakai, I., Takeuchi, K., Yamauchi, H., Narumi, H., Fujita, S.
(2002). Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood
100: 2926-2931
[Abstract][Full Text]
Baccarani, M., Rosti, G., de Vivo, A., Bonifazi, F., Russo, D., Martinelli, G., Testoni, N., Amabile, M., Fiacchini, M., Montefusco, E., Saglio, G., Tura, S.
(2002). A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood
99: 1527-1535
[Abstract][Full Text]
Savage, D. G., Antman, K. H.
(2002). Imatinib Mesylate -- A New Oral Targeted Therapy. NEJM
346: 683-693
[Full Text]
Mahon, F. X., Delbrel, X., Cony-Makhoul, P., Faberes, C., Boiron, J. M., Barthe, C., Bilhou-Nabera, C., Pigneux, A., Marit, G., Reiffers, J.
(2002). Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa. JCO
20: 214-220
[Abstract][Full Text]
Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P. C. A., Steegmann, J. L., Kluin-Nelemans, H. C., Thaler, J., Simonsson, B., Louwagie, A., Reiffers, J., Mahon, F. X., Montefusco, E., Alimena, G., Hasford, J., Richards, S., Saglio, G., Testoni, N., Martinelli, G., Tura, S., Baccarani, M.
(2001). Chronic myeloid leukemia and interferon-alpha : a study of complete cytogenetic responders. Blood
98: 3074-3081
[Abstract][Full Text]
Barthe, C., Mahon, F.-X., Gharbi, M.-J., Faberes, C., Bilhou-Nabera, C., Hochhaus, A., Reiffers, J., Marit, G.
(2001). Expression of interferon-{alpha} (IFN-{alpha}) receptor 2c at diagnosis is associated with cytogenetic response in IFN-{alpha}-treated chronic myeloid leukemia. Blood
97: 3568-3573
[Abstract][Full Text]
Jonasch, E., Haluska, F. G.
(2001). Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. The Oncologist
6: 34-55
[Abstract][Full Text]
Druker, B. J., Sawyers, C. L., Capdeville, R., Ford, J. M., Baccarani, M., Goldman, J. M.
(2001). Chronic Myelogenous Leukemia. ASH Education Book
2001: 87-112
[Abstract][Full Text]
Schandene, L., Roufosse, F., de Lavareille, A., Stordeur, P., Efira, A., Kennes, B., Cogan, E., Goldman, M.
(2000). Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood
96: 4285-4292
[Abstract][Full Text]
Reuben, J. M., Lee, B.-N., Johnson, H., Fritsche, H., Kantarjian, H. M., Talpaz, M.
(2000). Restoration of Th1 Cytokine Synthesis by T Cells of Patients with Chronic Myelogenous Leukemia in Cytogenetic and Hematologic Remission with Interferon-{{alpha}}. Clin. Cancer Res.
6: 1671-1677
[Abstract][Full Text]
Le Gouill, S., Talmant, P., Milpied, N., Daviet, A., Ancelot, M., Moreau, P., Harousseau, J.-L., Bataille, R., Avet-Loiseau, H.
(2000). Fluorescence In Situ Hybridization on Peripheral-Blood Specimens Is a Reliable Method to Evaluate Cytogenetic Response in Chronic Myeloid Leukemia. JCO
18: 1533-1538
[Abstract][Full Text]
Hensley, M. L., Peterson, B., Silver, R. T., Larson, R. A., Schiffer, C. A., Szatrowski, T. P.
(2000). Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013. JCO
18: 1301-1308
[Abstract][Full Text]
Giralt, S., Szydlo, R., Goldman, J. M., Veum-Stone, J., Biggs, J. C., Herzig, R. H., Klein, J. P., McGlave, P. B., Schiller, G., Gale, R. P., Rowlings, P. A., Horowitz, M. M.
(2000). Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the International Bone Marrow Transplant Registry. Blood
95: 410-415
[Abstract][Full Text]
Rodriguez, J., Cortes, J., Talpaz, M., O’Brien, S., Smith, T. L., Rios, M. B., Kantarjian, H.
(2000). Serum {beta}-2 Microglobulin Levels Are a Significant Prognostic Factor in Philadelphia Chromosome-positive Chronic Myelogenous Leukemia. Clin. Cancer Res.
6: 147-152
[Abstract][Full Text]
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., Talpaz, M., Tura, S.
(1999). An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology. Blood
94: 1517-1536
[Abstract][Full Text]
(1999). Monitoring Treatment and Survival in Chronic Myeloid Leukemia. JCO
17: 1858-1858
[Abstract][Full Text]
Mahon, F.X., Faberes, C., Pueyo, S., Cony-Makhoul, P., Salmi, R., Boiron, J.M., Marit, G., Bilhou-Nabera, C., Carrere, A., Montastruc, M., Pigneux, A., Bernard, Ph., Reiffers, J.
(1998). Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon-alpha. Blood
92: 4059-4065
[Abstract][Full Text]
The Italian Cooperative Study Group on Chronic Mye,
(1998). Long-Term Follow-Up of the Italian Trial of Interferon-alpha Versus Conventional Chemotherapy in Chronic Myeloid Leukemia. Blood
92: 1541-1548
[Abstract][Full Text]
Morton, A. J., Gooley, T., Hansen, J. A., Appelbaum, F. R., Bruemmer, B., Bjerke, J. W., Clift, R., Martin, P. J., Petersdorf, E. W., Sanders, J. E., Storb, R., Sullivan, K. M., Woolfrey, A., Anasetti, C.
(1998). Association Between Pretransplant Interferon-alpha and Outcome After Unrelated Donor Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase. Blood
92: 394-401
[Abstract][Full Text]
Hansen, J. A., Gooley, T. A., Martin, P. J., Appelbaum, F., Chauncey, T. R., Clift, R. A., Petersdorf, E. W., Radich, J., Sanders, J. E., Storb, R. F., Sullivan, K. M., Anasetti, C.
(1998). Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia. NEJM
338: 962-968
[Abstract][Full Text]
Hehlmann, R.
(1998). A Chance of Cure for Every Patient with Chronic Myeloid Leukemia?. NEJM
338: 980-982
[Full Text]
Yanagisawa, K., Yamauchi, H., Kaneko, M., Kohno, H., Hasegawa, H., Fujita, S.
(1998). Suppression of Cell Proliferation and the Expression of a bcr-abl Fusion Gene and Apoptotic Cell Death in a New Human Chronic Myelogenous Leukemia Cell Line, KT-1, by Interferon-alpha. Blood
91: 641-648
[Abstract][Full Text]
Schmidt, M., Nagel, S., Proba, J., Thiede, C., Ritter, M., Waring, J. F., Rosenbauer, F., Huhn, D., Wittig, B., Horak, I., Neubauer, A.
(1998). Lack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias. Blood
91: 22-29
[Abstract][Full Text]
Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.-F., Tanzer, J., Navarro, M., Bordessoule, D., Morice, P., Ifrah, N., Rochant, H., Vilque, J.-P., Delain, M., Bauters, F., Guilhot, J., The French Chronic Myeloid Leukemia Study Group,
(1997). Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia. NEJM
337: 223-229
[Abstract][Full Text]
Arico, M., Biondi, A., Pui, C.-H.
(1997). Juvenile Myelomonocytic Leukemia. Blood
90: 479-488
[Full Text]
Petzer, A.L., Eaves, C.J., Barnett, M.J., Eaves, A.C.
(1997). Selective Expansion of Primitive Normal Hematopoietic Cells in Cytokine-Supplemented Cultures of Purified Cells From Patients With Chronic Myeloid Leukemia. Blood
90: 64-69
[Abstract][Full Text]
Binder, D., Fehr, J., Hengartner, H., Zinkernagel, R. M.
(1997). Virus-induced Transient Bone Marrow Aplasia: Major Role of Interferon-alpha /beta during Acute Infection with the Noncytopathic Lymphocytic Choriomeningitis Virus. J. Exp. Med.
185: 517-530
[Abstract][Full Text]
Musashi, M., Abe, S., Yamada, T., Tanaka, J., Gotohda, Y., Maeda, S., Sato, Y., Morioka, M., Sakurada, K., Minagawa, T., Asaka, M., Miyazaki, T.
(1997). Spontaneous Remission in a Patient with Chronic Myelogenous Leukemia. NEJM
336: 337-339
[Full Text]
Muller, U, Steinhoff, U, Reis, L., Hemmi, S, Pavlovic, J, Zinkernagel, R., Aguet, M
(1994). Functional role of type I and type II interferons in antiviral defense. Science
264: 1918-1921
[Abstract]
The Italian Cooperative Study Group on Chronic Mye,
(1994). Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia. NEJM
330: 820-825
[Abstract][Full Text]
